Lectin-binding substance assay method and lectin-binding substance assay kit, and blocked labeled lectin used therein

Abstract

A method for measuring a lectin-associated substance in a sample, the method being characterized by including a measurement step in which a sample and blocked labeled lectin are brought into contact with each other, the blocked labeled lectin being provided with a water-soluble carrier formed from a first water-soluble polymer, and a labeling substance and lectin that are fixed to the water-soluble carrier.

Description

[Technical field]

[0001] The present invention relates to a method for measuring a lectin-binding substance, a kit for measuring a lectin-binding substance, and a blocked, labeled lectin for use therein. [Background technology]

[0002] In recent years, methods for measuring glycans or substances having glycans, such as glycoproteins, glycolipids, and free glycans, have been actively studied as monitoring markers for malignant diseases, such as tumor markers. Among these, from the viewpoint of being able to measure not only the quantitative changes of these analyte substances but also the qualitative changes due to the changes in the glycans, a measurement method using a lectin that binds to the glycan portion of the analyte or a measurement method combining this with a measurement using an antibody of the analyte has attracted attention. As an example of an analyte (lectin-binding substance) that can be measured using such a lectin, among α-fetoprotein (AFP), which is an oncofetal glycoprotein expressed in hepatitis, liver cirrhosis, hepatocellular carcinoma, etc., α-fetoprotein L3 (AFP-L3) having a glycan with fucose added (core fucose structure) is known to be a marker with high specificity for hepatocellular carcinoma. Currently, "Mutas Wako AFP-L3," which combines an antibody that binds to the AFP portion with a lectin (lentil lectin (LCA)) that binds to the core fucose structure, is manufactured and sold by Fujifilm Wako Pure Chemical Industries, Ltd. as a reagent for detecting AFP-L3 fractions. This reagent uses the LBA (Liquid-phase Binding Assay) method, which separates and measures immune complexes formed after antigen-antibody reactions in the liquid phase using ion exchange columns or electrophoresis, but it requires the use of dedicated equipment with low versatility designed to implement this method, which causes the problem of high measurement costs.

[0003] As another example of a method for measuring the lectin-binding substance, International Publication No. 2017 / 183711 (Patent Document 1) describes a method for capturing a lectin target molecule, which comprises binding a lectin to a lectin target molecule (lectin-binding substance) in the presence of a lectin-reactive glycan-containing entity.

[0004] In addition, in immunoassay methods using a complex of a probe such as an antibody and a labeling substance such as an enzyme, various studies have been conducted with the aim of increasing sensitivity. For example, as the complex, International Publication No. 2006 / 070732 (Patent Document 2) describes a blocked enzyme probe complex in which two or more molecules of a carrier having a molecular weight of 20,000 to 4,000,000 are bound via an enzyme, and a probe molecule is bound to the complex in which the enzyme is bound to the carrier. JP Patent Publication No. 2001-181299 (Patent Document 3) describes an enzyme-protein complex in which two or more enzymes are bound to a carrier, and at least one of the enzymes is bound to a protein that exhibits specific binding to other substances. In addition, for example, as measurement conditions, JP Patent Publication No. 2018-4323 (Patent Document 4) and JP Patent Publication No. 61-79164 (Patent Document 5) describe the coexistence of an activating factor such as dextran in an immunochemical reaction. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] International Publication No. 2017 / 183711 [Patent Document 2] International Publication No. 2006 / 070732 [Patent Document 3] JP 2001-181299 A [Patent Document 4] JP 2018-4323 A [Patent Document 5] Japanese Patent Application Publication No. 61-79164 Summary of the Invention [Problem to be solved by the invention]

[0006] However, there has been insufficient research on a method for easily measuring lectin-binding substances using lectins. In addition, when simply using lectins, there is a problem in that the affinity between lectins and glycans is weaker than that in antigen-antibody reactions, making it difficult to perform highly sensitive measurements using methods such as CLEIA (chemiluminescence enzyme immunoassay). Furthermore, in measurement methods using lectins, lectins nonspecifically bind to substances other than the target substance (for example, lectin-recognizing glycans bound to non-target proteins, etc.), resulting in high background and low specificity, which also makes it difficult to perform highly sensitive measurements.

[0007] The present invention has been made in view of the above-mentioned problems, and an object of the present invention is to provide a method and kit for measuring a lectin-binding substance, which are capable of measuring a lectin-binding substance in a sample simply and with high sensitivity, and a blocked labeled lectin for use therein. [Means for solving the problem]

[0008] The present inventors have found that in measuring lectin-binding substances in a sample, by using a complex (blocked labeled lectin) comprising a water-soluble carrier made of a water-soluble polymer and a labeled substance and lectin fixed to the water-soluble carrier, the measurement sensitivity of the lectin-binding substance can be sufficiently improved by simply contacting the complex with the sample, thereby completing the present invention.

[0009] The present invention, based on these findings, has the following features. (1) A method for measuring a lectin-binding substance in a sample, A method for measuring a lectin-binding substance, comprising a measurement step of contacting the sample with a blocked labeled lectin, the blocked labeled lectin comprising a water-soluble carrier made of a first water-soluble polymer and a labeled substance and a lectin immobilized on the water-soluble carrier. (2) The method for measuring a lectin-binding substance according to (1), wherein the measuring step is carried out in the presence of a second water-soluble polymer. (3) The method for measuring a lectin-binding substance according to (1) or (2), wherein the blocked labeled lectin is a combination of a high-molecular-weight blocked labeled lectin in which the weight-average molecular weight of the first water-soluble polymer is 200,000 or more, and a low-molecular-weight blocked labeled lectin in which the weight-average molecular weight of the first water-soluble polymer is less than 100,000. (4) The method for measuring a lectin-binding substance according to any one of (1) to (3), wherein the measuring step further comprises a step of contacting the sample with a labeled lectin comprising a labeling substance and a lectin. (5) A blocked labeled lectin for use in the method for measuring a lectin-binding substance according to any one of (1) to (4), comprising a water-soluble carrier made of a first water-soluble polymer and a labeled substance and a lectin immobilized on the water-soluble carrier. (6) A kit for measuring a lectin-binding substance in a sample, the kit comprising the blocked labeled lectin according to (5). (7) The kit for measuring a lectin-binding substance described in (6), wherein the blocked labeled lectin is a combination of a high-molecular-weight blocked labeled lectin in which the weight-average molecular weight of the first water-soluble polymer is 200,000 or more, and a low-molecular-weight blocked labeled lectin in which the weight-average molecular weight of the first water-soluble polymer is less than 100,000. (8) The kit for measuring a lectin-binding substance according to (6) or (7), further comprising a second water-soluble polymer. (9) The kit for measuring a lectin-binding substance according to any one of (6) to (8), further comprising a labeled lectin having a labeling substance and a lectin.

[0010] Although the reason why the above object is achieved by the configuration of the present invention is not entirely clear, the present inventors speculate as follows: In other words, in the blocked labeled lectin used in the measurement of a lectin-binding substance of the present invention, a lectin that binds to the lectin-binding substance and a labeling substance are immobilized on a water-soluble carrier made of a water-soluble polymer, and thus a complex is formed in which multiple lectins are connected by the water-soluble carrier, which is a polymer. When this is brought into contact with a lectin-binding substance in a sample, each of the multiple lectins binds to the lectin-binding sugar chain structure of the lectin-binding substance, which is the target substance. Therefore, even if the affinity at each binding point between the lectin and the lectin-binding sugar chain structure is weak, the occurrence of multiple binding points for one complex improves the affinity of the complex as a whole, and the lectin-binding substance can be measured with high sensitivity. Effect of the Invention

[0011] According to the present invention, it is possible to provide a method and kit for measuring a lectin-binding substance, which are capable of measuring a lectin-binding substance in a sample simply and with high sensitivity, and a blocked labeled lectin for use therein. [Brief description of the drawings]

[0012] [Figure 1] 1 is a curve showing the relationship between the count and the L3 antigen concentration in Examples 3-3 to 3-6. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] The present invention will be described in detail below based on preferred embodiments thereof.

[0014] The lectin-binding substance measurement method of the present invention is a method for measuring a lectin-binding substance in a sample, and is characterized by comprising a measurement step of contacting the sample with a blocked labeled lectin comprising a water-soluble carrier made of a first water-soluble polymer and a labeled substance and a lectin immobilized on the water-soluble carrier. The lectin-binding substance measurement kit of the present invention is a kit for measuring a lectin-binding substance in a sample, and is characterized by comprising the blocked labeled lectin. Furthermore, the blocked labeled lectin of the present invention is the blocked labeled lectin for use in the lectin-binding substance measurement method and lectin-binding substance measurement kit of the present invention.

[0015] [sample] The "sample" used in the lectin-binding substance measurement method of the present invention is not particularly limited as long as it is a sample in which a lectin-binding substance can be present. In general, examples of the sample include blood samples such as serum, plasma, and whole blood collected from a subject (preferably a human) for which a lectin-binding substance of interest is to be measured, such as a diagnostic subject; urine; stool; oral mucosa; pharyngeal mucosa; intestinal mucosa; and various biopsy samples. The sample according to the present invention is preferably an aqueous sample, such as serum or plasma. These samples may be diluted as necessary.

[0016] [Lectin-binding substances] In the present invention, the term "lectin-binding substance" refers to a glycan capable of binding to lectin (a glycan having a lectin-binding glycan structure) or a substance having such a glycan, and more specifically, examples of such a substance include a glycoprotein having a glycan capable of binding to lectin, a glycolipid having such a glycan, and a carbohydrate containing such a glycan.

[0017] Lectins are proteins that recognize specific sugar chain structures and exhibit binding activity. Lectins are known to be derived from animals (e.g., vertebrates and invertebrates), plants (e.g., legumes and grasses), and fungi (e.g., mushrooms and koji), and can be classified into fucose-specific lectins that have affinity for fucose, galectins that have affinity for galactose, and sialic acid-reactive lectins, depending on the sugar chain structure they have affinity for. More specifically, examples of lectins include European eel lectin (Anguilla anguilla agglutinin, AAA), Aleuria aurantia lectin (AAL), Agaricus blazei lectin (ABL), Agrocybe cylindracea galectin (ACG), Amaranthus caudatus lectin (ACL), Aspergillus oryzae lectin (AOL), Alum maculatum lectin (AML), garlic lectin (Allium sativum lectin, ASL), banana lectin (BanLec), Burkholderia cepacia lectin (BC2L), Bauhinia purpurea lectin (Bauhinia purpurea lectin, BPL), autumnale lectin, CA), Caragana arborescens agglutinin, CAA), Calystegia sepium lectin, Calsepa), Coprinopsis cinerea lectin, CGL2), Cicer arietinum agglutinin, CPA), Cytisus sscoparius lectin, CSA), Canavalia ensiformis lectin, Concanavalin A, ConA), Dolichos biflorus lectinagglutinin, DBA), Dictyostelium discoideum lectin, Discoidin I, Dictyostelium discoideum lectin, Discoidin II, Datura stramonium lectin, DSL, Sambucus nigra agglutinin, SNA, Erythrina cristagalli lectin, ECL, Euonymus europaeus lectin, EEL, Escherichia coli lectin, F17AG, Galanthus nivalis lectin, GNL, Griffonia simplicufolia lectin I (GSL I), Bandira bean lectin II (GSL II), Lobster lectin (Homarus americanus lectin, HMA), Helix pomatia agglutinin (HPA), Hippeastrum hybrid lectin (Hippeastrum hybrid lectin, HHL), Dutch iris lectin (Iris hybrid, IRA), Jackfruit lectin (Jacalin), Laburnum anagyroides lectin (LAL), Lima bean agglutinin (LBA), Lens culinaris agglutinin (LCA), Lotus tetragonolobus lectin (LTL), Tomato lectin (Lycopersicon esculentum lectin, LEL), Maackia amurensis lectin I leukoagglutinin lectin, Maackia amurensis lectin I, MAM), canine amurensis lectin II (Maackia amurensis agglutinin)lectin, Maackia amurensis lectin II (MAA), Marasmius oreades agglutinin (MOA), Maclura pomifera lectin (MPL), Narcissus pseudonarcissus lectin (NPL), Oryza sativa lectin (Orysata), Pseudomonas aeruginosa lectin I (PA-IL), Pseudomonas aeruginosa lectin II (PA-IIL), Phlebo- dia aureum lectin (PAL), Phaseolus vulgaris agglutinin-E,-L,-P, PHA-E,-L,-P, Peanut agglutinin (PNA), Pholiota lectin squarrosa lectin, PhoSL), Pleurocybella porrigens lectin, PPL, Pisum sativum agglutinin, PSA, Polyporus squamosus lectin 1a, PSL 1a, Psophocarpus tetragonolobus lectin I, PTL I, PTL II, Pokeweed mitogen, PWM, Ricinus communis agglutinin I, RCA I, RCA II, Robinia pseudoacacia agglutinin, RPA, Ralstonia solanacearum-Fuc lectin, RS-Fuc), Sambucus sieboldiana agglutinin, SAMB, Soybean agglutinin, SBA, Salvia horminum lectinagglutinin, SHA), Sophora japonica agglutinin, SJA, clary sage lectin, Salvia sclarea agglutinin, SSA, potato lectin, Solanum tuberosum lectin, STL, tulip lectin, TL, nettle lectin, Urtica dioica agglutinin, UDA, gorse lectin I, Ulex europaeus agglutinin I, UEA I, gorse lectin II, Vigna radiata agglutinin, VRA, Vicia villosa lectin, VVL, Wisteria floribunda agglutinin, WFA, and wheat germ agglutinin, WGA.

[0018] The lectin-binding substance according to the present invention is not particularly limited, but is preferably a glycoprotein or glycolipid used as a monitoring marker for malignant diseases, such as a tumor marker, and more preferably a glycoprotein having a sugar chain capable of binding to the lectin. Examples of the glycoprotein include glycoproteins derived from mammals, birds, reptiles, amphibians, fish, plants, insects, microorganisms, or viruses. More specifically, examples of the glycoprotein include α-fetoprotein (AFP-L3, etc.), basic fetoprotein (BFP), CA125, CA15-3, CA19-9, CA242, CA50, CA72.4, SPan-1, DUPAN-2, carcinoembryonic antigen (CEA), c-erB-2, cytokeratin 19 fragment (CYFRA), KL-6, elastase I, epithelial membrane antigen, ganglioside fucosylated GM1 (Fuc-GM1), Kallikrein-8, Matriptase, immunosuppressive acidic protein, neural cell adhesion molecule (NCAM), NCC-ST-439, nerve-specific enolase (NSE), prostatic acid phosphatase (PAP), protein induced by vitamin K absence or antagonist II (PIVKA-II), and tissue polypeptide. Examples of antigens include squamous cell carcinoma-associated antigen (SCC), prostate-specific antigen (PSA), sialyl Lex-i antigen (SLX), sialyl Tn antigen (STN), tissue polypeptide antigen (TPA), γGTP, various immunoglobulins, lacto-series carbohydrate antigens, gangliosides, transferrin, haptoglobin, hemopexin, thyroglobulin, human chorionic gonadotropin (hCG), carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), cytoskeleton-associated protein 4 (CKAP4), virus particles and virus-derived proteins, glypican, cadherin, integrin, various membrane proteins, various extracellular matrix constituent proteins, various enzymes, and various carbohydrate antigens, and one or more of these may be used alone or in combination.Among these, from the viewpoint of being more suitable for a method of specific diagnostic support for malignant diseases, the lectin-binding substance according to the present invention is preferably at least one selected from the group consisting of glycoproteins having a sugar chain capable of binding to a fucose-specific lectin, more preferably at least one selected from the group consisting of AFP-L3 and PSA (prostate-specific antigen), and even more preferably any one of these. Note that, it is preferable to exclude antibodies that specifically recognize lectins from the lectin-binding substances according to the present invention.

[0019] [Blocked labeled lectin] In the present invention, the "blocked labeled lectin" refers to a complex comprising a water-soluble carrier made of a water-soluble polymer, and a labeling substance and a lectin immobilized on the water-soluble carrier, and is a conjugate in which the water-soluble carrier, the labeling substance, and the lectin are directly or indirectly bound to the water-soluble carrier. In the blocked labeled lectin of the present invention, it is sufficient that the labeling substance and the lectin are carried on the water-soluble carrier, and the labeling substance and the lectin may be bound to the water-soluble carrier independently of each other, or the water-soluble carrier, the labeling substance, and the lectin may all be bound to the other two, the lectin may be bound to the water-soluble carrier via the labeling substance, or the labeling substance may be bound to the water-soluble carrier via the lectin.

[0020] [Water-soluble carrier] The water-soluble carrier contained in the blocked labeled lectin of the present invention mainly functions as a carrier for carrying the labeling substance and lectin, and is composed of a water-soluble polymer. The water-soluble polymer constituting the water-soluble carrier of the present invention (hereinafter referred to as "first water-soluble polymer") is not particularly limited as long as it is a water-soluble polymer that can immobilize and carry the labeling substance and lectin. In the present invention, the "water-soluble polymer" refers to a polymer compound having a solubility in water of more than 0.01 g / mL, preferably 0.05 g / mL or more, more preferably 0.1 g / mL or more at room temperature and normal pressure.

[0021] The first water-soluble polymer according to the present invention preferably has a weight-average molecular weight (weight-average molecular weight calculated as polystyrene by gel permeation chromatography (GPC), the same applies below) of 6,000 to 4,000,000, and more preferably 20,000 to 1,000,000, from the viewpoints of measurement sensitivity and water solubility. Furthermore, from the viewpoint that the concentration of the lectin-binding substance to be measured tends to be measurable with higher sensitivity even at low concentrations, a higher molecular weight is preferable, and a molecular weight of 20,000 to 1,000,000 is preferable, and a molecular weight of 50,000 to 700,000 is more preferable.

[0022] In addition, the blocked labeled lectin of the present invention is preferably a combination of a high-molecular-weight blocked labeled lectin in which the weight-average molecular weight of the first water-soluble polymer is 200,000 or more and a low-molecular-weight blocked labeled lectin in which the weight-average molecular weight of the first water-soluble polymer is less than 100,000 (more preferably 100,000 or less), and more preferably a combination of a high-molecular-weight blocked labeled lectin in which the weight-average molecular weight of the first water-soluble polymer is 200,000 to 700,000 (more preferably 250,000 to 500,000) and a low-molecular-weight blocked labeled lectin in which the weight-average molecular weight of the first water-soluble polymer is 20,000 to 100,000 (more preferably 50,000 to 70,000). By combining the high-molecular-weight blocked labeled lectin and the low-molecular-weight blocked labeled lectin, the measurable concentration range of the lectin-binding substance, which is the substance to be measured, tends to be wider. The present inventors speculate that this is because the low molecular weight blocked labeled lectins enter between the high molecular weight blocked labeled lectins, making the density of the blocked labeled lectins denser.

[0023] Furthermore, when the high molecular weight blocked labeled lectin and the low molecular weight blocked labeled lectin are combined as the blocked labeled lectin of the present invention, the mass ratio thereof (mass of the high molecular weight blocked labeled lectin:mass of the low molecular weight blocked labeled lectin) is preferably 10:1 to 1:10, more preferably 5:1 to 1:5, and even more preferably 3:1 to 1:3.

[0024] Furthermore, the blocked labeled lectin of the present invention may contain, as the first water-soluble polymer, a plurality of water-soluble polymers having different weight-average molecular weights in one blocked labeled lectin.

[0025] Examples of the first water-soluble polymer according to the present invention include polysaccharides such as dextran, aminodextran, Ficoll (trade name), dextrin, agarose, pullulan, various celluloses (e.g., hemicellulose, ligulin, etc.), chitin, and chitosan; β-galactosidase; thyroglobulin; hemocyanin; polylysine; polypeptide; DNA; and modified forms thereof (e.g., diethylaminoethyl dextran, sodium dextran sulfate, etc.), and one of these may be used alone or two or more may be used in combination. Among these, the first water-soluble polymer according to the present invention is preferably at least one selected from the group consisting of polysaccharides and modified forms thereof, more preferably at least one selected from the group consisting of dextran, aminodextran, and modified forms thereof, and even more preferably dextran, from the viewpoints of being inexpensive and available in large quantities, and being relatively easy to chemically process, such as by adding functional groups or performing coupling reactions.

[0026] [Labeling substance] The labeling substance contained in the blocked labeled lectin of the present invention mainly functions as a label for the blocked labeled lectin, and any labeling substance used in known immunological assays can be used without any particular limitation.

[0027] Examples of the labeling substance according to the present invention include enzymes; luminescent substances such as acridinium derivatives; fluorescent substances such as europium; fluorescent proteins such as allophycocyanin (APC) and phycoerythrin (R-PE); 125 Examples of the labeling substance include radioactive substances such as I; low molecular weight labeling substances such as fluorescein isothiocyanate (FITC) and rhodamine isothiocyanate (RITC); gold particles; avidin; biotin; latex; dinitrophenyl (DNP); and digoxigenin (DIG), and these may be used alone or in combination of two or more. For example, when an enzyme is used as the labeling substance, various detection and quantification can be performed depending on the substrate by adding a chromogenic substrate, a fluorescent substrate, a chemiluminescent substrate, or the like as a substrate. Examples of the enzyme include, but are not limited to, horseradish peroxidase (HRP), alkaline phosphatase (ALP), β-galactosidase (β-gal), glucose oxidase, and luciferase.

[0028] [Lectin] Examples of the lectin contained in the blocked labeled lectin of the present invention include the lectins listed in the above-mentioned lectin-binding substances, and are not particularly limited. They can be appropriately selected depending on the type of the lectin-binding substance to be measured, and may be one type alone or a combination of two or more types. Among these, the lectin contained in the blocked labeled lectin of the present invention is preferably at least one type selected from the group consisting of Lens lectin (LCA), Solanum umbellata lectin I (MAM), Acanthus platyphylla lectin (AAL), and Wisteria sieboldii lectin (WFA), and more preferably any one type among them, from the viewpoint of using the measurement of glycoproteins based on the cancer-specific sugar chain type appearing on the protein as an aid in the diagnosis of malignant tumors.

[0029] [Constitution and production method of blocked labeled lectin] In the blocked labeled lectin of the present invention, the content of the labeling substance is not particularly limited and can be appropriately adjusted depending on the measurement mechanism, etc.; however, in order to further improve the measurement sensitivity, it is preferable to set the number of molecules of the labeling substance bound to one molecule of the first water-soluble polymer as large as possible. For example, when the labeling substance is an enzyme, the mass of the labeling substance (when the first water-soluble polymer is a combination of two or more types, the total of the first water-soluble polymers; the same applies below) per 100 parts by mass of the first water-soluble polymer is preferably 100 to 1,000 parts by mass, more preferably 300 to 800 parts by mass.

[0030] In the blocked labeled lectin of the present invention, the content of lectin is not particularly limited, but in order to further improve the measurement sensitivity, it is preferable to set the number of lectin molecules binding to one molecule of the first water-soluble polymer as large as possible. For example, the mass of the lectin per 100 parts by mass of the first water-soluble polymer (when two or more types of lectins are used in combination, the total mass of the lectins) is preferably 100 to 2,000 parts by mass, and more preferably 300 to 1,500 parts by mass.

[0031] Furthermore, the blocked labeled lectin of the present invention preferably has a weight-average molecular weight per blocked labeled lectin molecule of 1,000,000 to 10,000,000, and more preferably 1,500,000 to 5,000,000. When the weight-average molecular weight is 1,000,000 or more, the measurement sensitivity tends to be higher, while when it is 10,000,000 or less, aggregation in an aqueous solution tends to be more sufficiently suppressed.

[0032] The blocked labeled lectin of the present invention can be produced by immobilizing the labeling substance and the lectin on the water-soluble carrier. As the production method, a conventionally known method or a method similar thereto can be appropriately adopted, and the labeling substance and the lectin (hereinafter, sometimes collectively referred to as "supported substance") may be directly or indirectly immobilized on the water-soluble carrier.

[0033] Examples of the method for directly immobilizing the supported substance on the water-soluble carrier include a method in which an active group such as a carboxy group, an epoxy group, a tosyl group, an amino group, a hydroxy group, an isothiocyanate group, an isocyanate group, an azide group, an aldehyde group, a carbonate group, an allyl group, an aminooxy group, a maleimide group, a thiol group, or a pyridyl disulfide group is added to the supported substance and / or the first water-soluble polymer constituting the water-soluble carrier, or a method in which a water-soluble polymer having such an active group is used as the supported substance and / or the water-soluble carrier and immobilized by a covalent bond using the active group. The supported substance and the first water-soluble polymer to which the active group is added may be commercially available as they are, or may be prepared by introducing the active group into the surface of the supported substance and the water-soluble polymer under appropriate reaction conditions. As an example, the introduction of a thiol group can be carried out using a commercially available reagent such as S-acetylmercaptosuccinic anhydride or 2-iminothiolane hydrochloride. Furthermore, introduction of a maleimide group into an amino group on the first water-soluble polymer constituting the supported substance and / or the water-soluble carrier can be carried out using a commercially available reagent such as N-(6-maleimidocaproyloxy)succinimide or N-(4-maleimidobutyryloxy)succinimide. Introduction of a pyridyl disulfide group can be carried out using a commercially available reagent such as N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP), N-{6-[3-(2-pyridyldithio)propionamido]hexanoyloxy}sulfosuccinimide, sodium salt (Sulfo-AC5-SPDP). Furthermore, the pyridyl disulfide group can also be introduced by reducing it after introduction to form a thiol group.

[0034] Furthermore, examples of the method for indirectly immobilizing the supported substance to the water-soluble carrier include polyhistidine, polyethylene glycol, an oligopeptide containing cysteine ​​and / or lysine, a linker molecule having the active group (e.g., hydrazine salt, hydrazide, AMAS (N-α-maleimidoacet-oxysuccinimide ester), BMPS (N-β-maleimidopropyl-oxysuccinimide ester), GMBS (N-γ-maleimidobutyryl-oxysuccinimide ester), MBS (m-maleimidobenzoyl-N-hydroxysuccinimide ester), SMCC (succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate), EMCS (N-ε-maleimidocaproyl-oxysuccinimide ester), SMPB (succinimidyl 4-(p-maleimidophenyl)butyrate), SMPH (succinimidyl 6-((beta-maleimidopropionamido)hexanoate)), LC-SMCC(succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxy-(6-amidocaproate)), Sulfo-KMUS(N-κ-maleimidoundecanoyl-oxysulfosuccinimide ester), SIA(succinimidyl iodoacetate), SBAP(succinimidyl 3-(bromoacetamido)propionate), SIAB(succinimidyl (4-iodoacetyl)aminobenzoate), Sulfo-SANPAH(sulfosuccinimidyl 6-(4'-azido-2'-nitrophenylamino)hexanoate), SDA(succinimidyl 4,4'-azipentanoate), Sulfo-SDAD(sulfosuccinimidyl 2-((4,4'-azipentanamido)ethyl)-1,Examples of such methods include immobilizing the ligand via a linker such as 3'-dithiopropionate, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), N-β-maleimidopropionic acid hydrazide (BMPH), N-ε-maleimidocaproic acid hydrazide (EMCH), 4-(4-N-maleimidophenyl)butyric acid hydrazide (MPBH), N-κ-maleimidooundecanoic acid hydrazide (KMUH), 3-(2-pyridyldithio)propionyl hydrazide (PDPH), p-maleimidophenyl isocyanate (PMPI), and succinimidyl-[4-(psoralen-8-yloxy)]-butyrate (SPB). The selection and size of the linker can be appropriately set in consideration of the strength of the bond with the supported substance and the steric hindrance caused by immobilizing the supported substance on the water-soluble carrier.

[0035] In the method for producing a blocked labeled lectin of the present invention, the labeling substance and the lectin may be immobilized on the water-soluble carrier at the same time, or may be immobilized separately and sequentially. From the viewpoint of ease of production and ease of control of the amounts of the labeling substance and the lectin, however, it is preferable to immobilize one of them on the water-soluble carrier before immobilizing the other.

[0036] The blocked labeled lectin of the present invention can also be produced by immobilizing the labeled substance and the lectin on separate water-soluble carriers, and binding the labeled substance immobilized on one water-soluble carrier (blocked labeled substance) to the lectin immobilized on the other water-soluble carrier (blocked lectin) directly or via the linker or the like.

[0037] Such a production method is not particularly limited, and for example, as described in the following examples, when the labeling substance is an enzyme and the first water-soluble polymer is a polysaccharide or glycoprotein, the first water-soluble polymer is first oxidized with an oxidizing agent such as sodium periodate to give an aldehyde group, reacted with hydrazine hydrochloride, and then reacted with a reducing agent such as dimethylamine borane (DMAB) to hydrazinate. Meanwhile, the enzyme is also oxidized with an oxidizing agent such as sodium periodate to give an aldehyde group to its sugar chain. Next, the hydrazine residue given above is reacted with the aldehyde group to form a hydrazone bond, thereby obtaining a first water-soluble polymer-enzyme conjugate. The obtained first water-soluble polymer-enzyme conjugate is treated with a crosslinker (e.g., SM(PEG)4, SMCC, etc.) having N-hydroxysuccinimide and maleimide groups at each end to introduce a maleimide group. On the other hand, the lectin is thiolated with a thiolation reagent to give a thiol group, or in the case of a lectin having a disulfide bond in the molecule, the thiol group is obtained by reduction. Finally, the maleimide group introduced into the first water-soluble polymer-enzyme conjugate is bound to the thiol group given to the lectin, thereby covalently binding the first water-soluble polymer (water-soluble carrier)-enzyme-lectin. According to this method, a product is obtained in which two or more molecules of the first water-soluble polymer are bound via the enzyme, and the lectin is bound to the first water-soluble polymer. The ratio of the first water-soluble polymer, labeling substance, and lectin to be subjected to these reactions can be appropriately selected so as to achieve the preferred range of each content in the above-mentioned blocked labeled lectin.

[0038] <Lectin binding substance measurement method> The method for measuring a lectin-binding substance of the present invention includes a measuring step of contacting the blocked labeled lectin of the present invention with the sample. In the present invention, "measurement" includes not only detection for confirming the presence or absence of a lectin-binding substance, but also quantification or semi-quantification of the amount of the lectin-binding substance.

[0039] In the present invention, the measurement of a lectin-binding substance is carried out by detecting a signal generated by a labeling substance and, if necessary, quantifying the signal. The "signal" includes coloration (color development), reflected light, luminescence, fluorescence, radiation from a radioisotope, and the like, and includes signals that can be confirmed by the naked eye as well as signals that can be confirmed by a measurement method or device depending on the type of signal. According to the method for measuring a lectin-binding substance of the present invention, the measurement sensitivity is high and the intensity of the signal generated by the labeling substance is sufficiently strong. Therefore, the measurement can be carried out using an automated immunoassay device that is commercially available for general-purpose immunoassay methods.

[0040] In the method for measuring a lectin-binding substance of the present invention, when the sample is a blood sample such as serum, plasma, or whole blood, it is preferable that the sample is subjected to a purification treatment and then subjected to the measurement step. That is, the method for measuring a lectin-binding substance of the present invention preferably comprises a purification treatment and the measurement step. The purification treatment is not particularly limited, but preferably includes the following purification treatments.

[0041] [Refining process] In the method for measuring a lectin-binding substance of the present invention, before measuring a lectin-binding substance using a lectin, the sample is subjected to the following purification treatment: a capture step of contacting the sample with a capture carrier, the capture carrier comprising a water-insoluble carrier and a molecule immobilized on the water-insoluble carrier, the molecule being capable of capturing a lectin-binding substance, to capture the lectin-binding substance on the capture carrier; A washing step for removing impurities not bound to the capture carrier; a releasing step of releasing the lectin-binding substance from the capture carrier to obtain a prepared sample; It is preferable to carry out a treatment including the steps of:

[0042] [Capture carrier (carrier on which target substance capture molecules are immobilized)] In the present invention, a "capture carrier" refers to a complex comprising a water-insoluble carrier and a molecule immobilized on the water-insoluble carrier, the molecule being capable of capturing a lectin-binding substance, and a conjugate in which the water-insoluble carrier and the molecule are directly or indirectly bound to each other.

[0043] (Target substance capture molecule) In the present invention, the term "molecule capable of capturing a lectin-binding substance" refers to a molecule capable of binding to a lectin-binding substance and capturing the lectin-binding substance as a target substance (hereinafter, sometimes referred to as "target substance capturing molecule"). The target substance capturing molecule is not particularly limited as long as it has the ability to bind to the lectin-binding substance, and examples of the target substance capturing molecule include antibodies, binding proteins (protein A, protein G, protein L, etc.), receptor proteins, and nucleic acids. The antibody may be a polyclonal antibody or a monoclonal antibody. In the present invention, the term "antibody" includes complete antibodies, antibody fragments (e.g., Fab, Fab', F(ab')2, Fv, single-chain antibodies, diabodies, etc.), and low molecular weight antibodies to which the variable regions of antibodies are bound. In addition, in the purification process, it is particularly desirable to wash and remove glycan-containing components other than the target substance, so that it is preferable to remove lectins having glycan binding properties from the target substance capturing molecule.

[0044] Furthermore, in the capture carrier according to the present invention, the target substance capture molecule used in the purification process may be a molecule that specifically binds only to the glycan portion that is recognized and bound by lectin (e.g., an antibody that can recognize and bind to the same site as lectin), or a molecule that can recognize and bind to a portion of the lectin-binding substance other than the glycan portion (e.g., the protein portion of the glycoprotein, the lipid portion of the glycolipid) or a portion that includes the glycan portion as a part thereof, but is preferably a molecule that can recognize and bind to a portion of the lectin-binding substance other than the glycan portion, and is preferably, for example, an anti-protein antibody against the protein portion of the glycoprotein (e.g., an anti-AFP antibody, an anti-PSA antibody). Therefore, the target substance capture molecule may be a molecule that can capture, in addition to the lectin-binding substance (e.g., AFP-L3, PSA (prostate-specific antigen)), a substance obtained by removing the glycan portion that is recognized and bound by lectin from the lectin-binding substance (e.g., only the protein portion of AFP, AFP-L1, and PSA).

[0045] The target substance capture molecule can be produced by appropriately adopting and improving a conventionally known production method, and a generally available one may be used as appropriate. For example, when the lectin-binding substance is AFP-L3, a commercially available anti-AFP monoclonal antibody, etc. may be used as appropriate.

[0046] (Non-water-soluble carrier) The water-insoluble carrier contained in the capture carrier mainly functions as a carrier for supporting and immobilizing the target substance capture molecule, and is a water-insoluble substance. In the present invention, the term "water-insoluble substance" refers to a substance that is insoluble in water (having a solubility in water of 0.001 g / mL or less, preferably 0.0001 g / mL or less, the same applies below) at room temperature and normal pressure.

[0047] The material of such a water-insoluble carrier can be any material generally used in immunological measurements, and is not particularly limited. For example, at least one selected from the group consisting of high molecular weight polymers (polystyrene, (meth)acrylic acid esters, polymethyl methacrylate, polyimide, nylon, etc.), gelatin, glass, latex, silica, metals (gold, platinum, etc.), and metal compounds (iron oxide, cobalt oxide, nickel ferrite, etc.) can be mentioned. In addition, the material of the water-insoluble carrier may be a composite of these materials or a composite of these materials with other materials, and may be, for example, an organic-inorganic composite material consisting of at least one organic polymer selected from the group consisting of high molecular weight polymers, gelatin, and latex, and at least one metal compound selected from the group consisting of iron oxide (spinel ferrite, etc.), cobalt oxide, and nickel ferrite. Furthermore, the water-insoluble carrier may be surface-modified with an active group such as a carboxy group, an epoxy group, a tosyl group, an amino group, a hydroxy group, an isothiocyanate group, an isocyanate group, an azide group, an aldehyde group, a carbonate group, an allyl group, an aminooxy group, a maleimide group, or a thiol group.

[0048] In the present invention, the shape of the water-insoluble carrier is not particularly limited, and may be, for example, any of a plate, a fiber, a membrane, a particle, etc., but from the viewpoint of reaction efficiency, it is preferable that it is a particle, and from the viewpoint of automation and shortening the time, it is more preferable that it is a magnetic particle. As such a water-insoluble carrier, a conventionally known carrier can be appropriately used, and a commercially available carrier can also be appropriately used.

[0049] (Structure and manufacturing method of capture carrier) The content of the target substance capture molecule in the capture carrier is not particularly limited and can be adjusted as appropriate depending on factors such as the ease of binding between the target substance capture molecule and the lectin-binding substance; for example, the mass of the target substance capture molecule (the total mass of the target substance capture molecule when two or more types of target substance capture molecules are combined) per 100 parts by mass of the water-insoluble carrier (preferably particles) (the total mass of the water-insoluble carrier when two or more types of water-insoluble carriers are combined) is preferably 0.1 to 10 parts by mass, and more preferably 1 to 5 parts by mass.

[0050] The capture carrier can be manufactured by immobilizing the target substance capture molecule on the water-insoluble carrier. As such a manufacturing method, a conventionally known method or a method similar thereto can be appropriately adopted, and the target substance capture molecule may be directly immobilized on the water-insoluble carrier, or may be indirectly immobilized. In the case of direct immobilization, for example, the water-insoluble carrier and / or the target substance capture molecule may have an active group such as a carboxyl group, an epoxy group, a tosyl group, an amino group, a hydroxyl group, an isothiocyanate group, an isocyanate group, an azide group, an aldehyde group, a carbonate group, an allyl group, an aminooxy group, a maleimide group, or a thiol group, or the active group may be added as necessary, and the target substance capture molecule may be directly immobilized on the water-insoluble carrier by binding them. In the case of indirect immobilization, for example, a linker that binds to the target substance capture molecule may be immobilized on the water-insoluble carrier, and the target substance capture molecule may be bound to the linker, thereby indirectly immobilizing the target substance capture molecule on the water-insoluble carrier. The linker is not particularly limited, and examples thereof include a secondary antibody capable of binding to a target substance capturing molecule, protein G, protein A, a photocleavable photocleavable linker, and a linker molecule having the active group (e.g., hydrazine salt, hydrazide, AMAS, BMPS, GMBS, MBS, SMCC, EMCS, SMPB, SMPH, LC-SMCC, Sulfo-KMUS, SIA, SBAP, SIAB, Sulfo-SANPAH, SDA, Sulfo-SDAD, EDC, NHS, BMPH, EMCH, MPBH, KMUH, PDPH, PMPI, and SPB). In addition, the target substance capturing molecule may be modified in some way, and a substance that captures the modified portion may be immobilized on the water-insoluble carrier to immobilize the target substance capturing molecule on the water-insoluble carrier. For example, a representative example of the modified portion includes biotin, and a representative example of the substance that captures the modified portion includes streptavidin, but the present invention is not limited thereto. The ratio of the water-insoluble carrier and the target substance-capturing molecule to be subjected to these reactions can be appropriately selected so as to achieve the preferred range of the ratio in the capture carrier described above.If necessary, the non-water-soluble carrier may be blocked with a suitable blocking agent (e.g., bovine serum albumin, gelatin, etc.) for the purpose of preventing non-specific adsorption to the target substance capture molecule or the non-water-soluble carrier. Furthermore, as such a capture carrier, for example, commercially available particles such as anti-AFP antibody-bound particles, anti-PSA antibody-bound particles, etc. may be used appropriately.

[0051] [Capturing process] In the capturing step, the capture carrier is brought into contact with the sample, and the lectin-binding substance is captured on the capture carrier via binding between the lectin-binding substance and the target substance capturing molecule. The method for contacting the capture carrier with the sample is not particularly limited, and a conventionally known method or a method similar thereto can be appropriately adopted, for example, a method in which the sample is injected into the non-water-soluble carrier when the capture carrier is a plate and the capture carrier is a target substance capturing molecule immobilized plate, or a method in which the target substance capturing molecule immobilized particle is added to the sample when the non-water-soluble carrier is a particle and the capture carrier is a target substance capturing molecule immobilized particle.

[0052] The sample may be used after diluting with a sample dilution solution, or when the capture carrier is a particle having the target substance capture molecule fixed thereon, it may be used after suspending in a particle suspension medium (particle liquid), and further, other reaction buffers may be appropriately added to the reaction system (e.g., antigen-antibody reaction system) between the capture carrier and the sample. The sample dilution solution, particle suspension medium, and reaction buffer are not particularly limited, and examples thereof include known buffer solutions (sodium phosphate buffer, MES, Tris, CFB, MOPS, PIPES, HEPES, tricine buffer, bicine buffer, glycine buffer, etc.), and the particle suspension medium and reaction buffer may each independently contain a stabilized protein such as BSA or serum, etc.

[0053] In the reaction between the capture carrier and the sample in the capture step, the content (final concentration) of the capture carrier in the reaction solution containing the capture carrier and the sample (the total of the capture carriers when two or more types of capture carriers are combined, the same applies below) is not particularly limited and is adjusted appropriately depending on the type and concentration of the sample, the purpose of the purification process, etc., but from the viewpoint of efficiently recovering the substance captured by the target substance capture molecule in a short period of time, it is preferably, for example, 0.01 to 1.5 mass%, more preferably 0.05 to 1 mass%, and even more preferably 0.1 to 0.5 mass%.

[0054] The conditions for the capture step are not particularly limited and can be adjusted as appropriate. For example, the capture step can be performed at room temperature to 45°C, preferably 20 to 37°C, at a pH of about 6 to 9, preferably 7 to 8, for about 5 seconds to 10 minutes, preferably 30 seconds to 5 minutes, but are not limited to these conditions.

[0055] [Cleaning process] In the washing step, the target substance bound to the capture carrier (including at least a lectin-binding substance when the sample contains this) is separated from other impurities not bound to (not captured by) the capture carrier, and the impurities are removed. The method for removing the impurities is not particularly limited, and a conventionally known method or a method similar thereto can be appropriately adopted. For example, when the water-insoluble carrier is a plate and the capture carrier is a plate on which a target substance capture molecule is immobilized, a method of removing the liquid phase (supernatant) from the plate after the capture step can be mentioned, and when the water-insoluble carrier is a particle and the capture carrier is a particle on which a target substance capture molecule is immobilized, a method of recovering the particles by centrifugation or magnetic collection after the capture step and removing the liquid phase (supernatant) can be mentioned. In addition, in the washing step, injection and removal of a washing solution can be repeated as necessary. The washing solution may be, for example, a known neutral (preferably pH 6 to 9) buffer solution (such as sodium phosphate buffer, MES, Tris, CFB, MOPS, PIPES, HEPES, tricine buffer, bicine buffer, or glycine buffer), or may contain a stabilizing protein such as BSA or a surfactant.

[0056] [Release process] In the releasing step, the lectin-binding substance bound to the capture carrier is released from the capture carrier to obtain a prepared sample containing the re-released lectin-binding substance as a sample to be subjected to the measurement step. The method for releasing the lectin-binding substance from the capture carrier is not particularly limited, and examples thereof include a method of making the reaction system acidic or alkaline; a method of cleaving a photocleavable linker by light irradiation when the linker is used; a method using a surfactant; a method using a protein denaturant; a method of applying heat; and a method using a combination of the above methods.

[0057] For example, when the reaction system is made acidic, an eluate having a pH of preferably 4 or less (more preferably, pH 3 to 1) is brought into contact with the capture carrier to which the lectin-binding substance is bound, and when the reaction system is made alkaline, an eluate having a pH of preferably 9 or more (more preferably, pH 10 to 14) is brought into contact. Examples of the eluate include those containing an acidifying agent (e.g., hydrochloric acid, sulfuric acid, acetic acid, citric acid) or an alkalizing agent (e.g., sodium hydroxide, potassium hydroxide, magnesium hydroxide). In these cases, it is preferable to subsequently add a neutralizing agent (e.g., hydrochloric acid, sulfuric acid, acetic acid, citric acid, sodium hydroxide, potassium hydroxide, magnesium hydroxide, or a known buffer solution prepared to be alkaline or acidic) to the eluate to neutralize the reaction system.

[0058] Other conditions for the release step are not particularly limited and can be adjusted appropriately depending on the method. For example, the release step can be performed at room temperature to 37°C, preferably 20 to 37°C, for about 5 seconds to 10 minutes, preferably 30 seconds to 5 minutes, but is not limited to these conditions.

[0059] [Measurement process] The principle of the method for measuring a lectin-binding substance of the present invention may be any of the same principles as those of the sandwich method, competitive method, and immunoturbidimetric method of immunological measurement. In the method for measuring a lectin-binding substance of the present invention, when quantifying a lectin-binding substance in a sample, a method using a microplate or particles as a carrier, such as ELISA, digital ELISA, CLEIA (chemiluminescent enzyme immunoassay), CLIA (chemiluminescent immunoassay), ECLIA (electrochemical immunoassay), or RIA (radioimmunoassay), is generally adopted, and detection and quantification according to the type of the labeled substance are performed, and the results are compared with the measured value of a standard sample. On the other hand, from the viewpoint of detecting a lectin-binding substance more simply and quickly, a method such as immunochromatography may be adopted as the sandwich method.

[0060] From the viewpoint of tending to construct a detection system with higher sensitivity and specificity, the method for measuring a lectin-binding substance of the present invention is preferably a sandwich method in which an antibody capable of capturing a lectin-binding substance is used, and either this or a blocked labeled lectin is used as a capturer and the other as a detector (label) to measure the lectin-binding substance. Examples of the sandwich method include a two-step forward sandwich method (the reaction between the capturer and the lectin-binding substance in the sample, and the reaction between the lectin-binding substance bound to the capturer and the detector are carried out sequentially), a reverse sandwich method (the reaction between the detector and the lectin-binding substance in the sample is carried out in advance, and the resulting complex is reacted with the capturer), and a one-step method (the reaction between the capturer, the lectin-binding substance in the sample, and the detector are carried out simultaneously in one step), and any of these can be used.

[0061] More preferably, the forward sandwich method can be carried out as follows. First, an antibody capable of capturing a lectin-binding substance is used as a capturer (capture antibody), and the capturer is brought into contact with a non-water-soluble carrier on which the capturer is immobilized, and the lectin-binding substance in the sample is allowed to bind (first reaction step). After that, if necessary, the lectin-binding substance that has not bound to the capture antibody and impurities are removed with an appropriate washing solution (e.g., buffer solution, etc.). Next, the blocked labeled lectin of the present invention is used as a detector, and the lectin-binding substance captured by the capture antibody is allowed to bind (secondary reaction step). By this reaction, an immune complex containing the capture antibody-lectin-binding substance-blocked labeled lectin is formed on the non-water-soluble carrier. The unbound detector (blocked labeled lectin) is washed with a washing solution, and then the labeled substance of the detector is measured by a predetermined method. For example, when the labeled substance contained in the blocked labeled lectin is an enzyme, a chromogenic or luminescent substrate corresponding to the enzyme is added, and the enzyme is reacted with the substrate to measure the signal.

[0062] The "antibody capable of capturing a lectin-binding substance" used in the sandwich method includes the same antibodies as those listed in the target substance capturing molecule. From the viewpoint of further improving the measurement accuracy, the antibody capable of capturing a lectin-binding substance used in the measurement step is preferably an antibody that recognizes and binds to a portion of the lectin-binding substance other than the glycan portion (e.g., a protein portion of the glycoprotein, a lipid portion of the glycolipid), rather than an antibody that specifically binds only to the glycan portion recognized and bound by the lectin (i.e., an antibody that recognizes or physically coats and binds to the same portion as the lectin) or an antibody that recognizes and binds to a portion that includes the glycan portion as a part thereof. In addition, an antibody that does not have a glycan structure recognized by the lectin, such as a Fab, Fab', or F(ab')2 fragment, is also preferable. Furthermore, a complete antibody may be used as the antibody capable of capturing a lectin-binding substance used in the measurement step, but since the complete antibody has a glycan structure, it cannot be denied that the complete antibody may cause a non-specific reaction with the lectin, thereby increasing the background. Therefore, it is more preferable to prepare an antigen-binding fragment that does not have a sugar chain structure, or to destroy the sugar chains on the antibody in advance.

[0063] Furthermore, the "water-insoluble carrier" used in the above sandwich method is not particularly limited as long as it can immobilize and support the antibody and is insoluble in water at room temperature and normal pressure, and examples of the water-insoluble carrier include those similar to those listed as the water-insoluble carrier contained in the capture carrier in the above purification process.

[0064] Furthermore, the "insoluble carrier having a capture antibody immobilized thereon" used in the above-mentioned sandwich method can be manufactured in the same manner as the method of immobilizing the target substance capture molecule to the insoluble carrier in the above-mentioned purification process (the method of manufacturing the capture carrier).

[0065] In the lectin-binding substance measurement method of the present invention, the contacting method can be any conventionally known method or a method based thereon, as appropriate. For example, when the water-insoluble carrier is a plate, the sample and the blocked labeled lectin can be injected into the plate, or when the water-insoluble carrier is particles, the particle liquid can be mixed with the sample and the blocked labeled lectin solution all at once or sequentially.

[0066] In the lectin-binding substance measurement method of the present invention, in the measurement step, i.e., in the reaction between the blocked labeled lectin and the lectin-binding substance, the content (final concentration) of the blocked labeled lectin in a reaction solution containing the blocked labeled lectin and the lectin-binding substance (when the blocked labeled lectin is a combination of two or more types, the total of the blocked labeled lectins; the same applies hereinafter) is not particularly limited and is appropriately adjusted depending on the type, concentration, and the like of the sample. However, from the viewpoint that an excessive use may cause a high background signal, the content is preferably, for example, 0.001 to 10 μg / mL, more preferably 0.01 to 5 μg / mL, and even more preferably 0.1 to 1 μg / mL.

[0067] In the lectin-binding substance measurement method of the present invention, other conditions for the measurement step are also not particularly limited and can be adjusted as appropriate. For example, the reaction between the blocked labeled lectin and the lectin-binding substance can be carried out at room temperature to 37°C, preferably 20 to 37°C, at pH 5.0 to 7.0, preferably 5.5 to 6.5, for about 3 to 120 minutes, preferably about 5 to 10 minutes, but is not limited to these conditions.

[0068] [Second Water-Soluble Polymer] In the lectin-binding substance measurement method of the present invention, the measurement step, i.e., the reaction between the blocked labeled lectin and the lectin-binding substance, is preferably carried out in the presence of a water-soluble polymer, i.e., under conditions in which the water-soluble polymer, the blocked labeled lectin, and the sample (lectin-binding substance) coexist.

[0069] The water-soluble polymer that is preferably allowed to coexist with the blocked labeled lectin is different from the first water-soluble polymer constituting the water-soluble carrier, and is a free water-soluble polymer that does not carry the labeled substance or lectin (hereinafter referred to as "second water-soluble polymer"). In the method for measuring a lectin-binding substance of the present invention, the measurement sensitivity can be further improved by allowing the second water-soluble polymer to coexist in the measurement step.

[0070] The second water-soluble polymer may be the same as the first water-soluble polymer, and may be one of them alone or a combination of two or more. It may also be the same type of polymer as the first water-soluble polymer. Among these, the second water-soluble polymer is preferably at least one selected from the group consisting of polysaccharides and modified products thereof, more preferably at least one selected from the group consisting of dextran, aminodextran, and modified products thereof, and even more preferably dextran, from the viewpoint of a tendency to further improve the measurement sensitivity.

[0071] From the viewpoint of tending to further improve measurement sensitivity, the weight average molecular weight of the second water-soluble polymer is preferably 500,000 to 5,000,000, more preferably 1,000,000 to 3,000,000, and even more preferably 1,500,000 to 2,500,000.

[0072] When a second water-soluble polymer is allowed to coexist in the measurement step, the second water-soluble polymer may be added in advance to the sample or sample dilution solution, or may be added in advance to a solution of the blocked labeled lectin, or these may be mixed with a solution of the second water-soluble polymer. In this case, the amount of the second water-soluble polymer is not particularly limited, but the content of the second water-soluble polymer in a reaction solution containing the sample, the blocked labeled lectin, and the second water-soluble polymer (when the second water-soluble polymer is a combination of two or more types, the total amount of the second water-soluble polymers) is preferably 0.01 to 10 w / v%, more preferably 0.5 to 3 w / v% (w / v%: weight / volume (g / mL) percent, the same applies below).

[0073] [Labeled lectin] In the method for measuring a lectin-binding substance of the present invention, it is preferable that the measurement step further includes a step of contacting the sample with a labeled lectin comprising a labeling substance and a lectin, that is, under conditions in which the labeled lectin, the blocked labeled lectin, and the sample (lectin-binding substance) coexist, the blocked labeled lectin is reacted with the lectin-binding substance and the labeled lectin is reacted with the lectin-binding substance. In the method for measuring a lectin-binding substance of the present invention, the presence of a labeled lectin in the measurement step can further improve the measurement sensitivity. The present inventors speculate that this is because the presence of an excess of labeled lectin in the reaction system promotes the reaction between the lectin-binding substance and the blocked labeled lectin in the binding direction, and because the labeled lectin, which is a low molecular weight substance, is able to bind to a lectin-binding substance to which the blocked labeled lectin, which is a high molecular weight substance, cannot bind due to steric hindrance.

[0074] In the present invention, the "labeled lectin" that is preferably allowed to coexist with the blocked labeled lectin is a complex comprising a labeling substance and a lectin, and is a conjugate in which the labeling substance and the lectin are directly or indirectly bound to each other. The labeled lectin differs from the blocked labeled lectin of the present invention in that it does not comprise the water-soluble carrier.

[0075] The labeling substance contained in the labeled lectin may be the same as those exemplified as the labeling substance contained in the blocked labeled lectin of the present invention, and may be one of these alone or a combination of two or more of them. In addition, it is preferable that the labeling substance is the same as the labeling substance contained in the blocked labeled lectin.

[0076] Examples of the lectin contained in the labeled lectin include the same lectins as those listed as the lectins contained in the blocked labeled lectin of the present invention, and one of these may be used alone or two or more may be used in combination. In addition, it is preferable that the lectin is the same type as the lectin contained in the blocked labeled lectin. Among these, the lectin contained in the labeled lectin is preferably at least one selected from the group consisting of Lens lectin (LCA), Mucor elegans lectin I (MAM), Acanthus platyphylla lectin (AAL), and Wisteria sieboldii lectin (WFA), and more preferably any one of these.

[0077] In the labeled lectin, the content ratio of the labeling substance to the lectin is not particularly limited and can be appropriately adjusted depending on the measurement mechanism, etc.; for example, when the labeling substance is an enzyme, the content ratio of the labeling substance to the lectin (mass of labeling substance: mass of lectin; when the labeling substance and the lectin are a combination of two or more kinds, the content ratio is independently the total of the labeling substance and the lectin) is preferably 50:1 to 1:50, more preferably 10:1 to 1:10, and further preferably 5:1 to 1:5.

[0078] The labeled lectin can be produced by binding the labeling substance to the lectin. As the production method, a conventionally known method or a method similar thereto can be appropriately adopted, and the labeling substance and the lectin may be directly or indirectly immobilized. Examples of such a method include the same methods as those mentioned as the method for producing the blocked labeled lectin of the present invention. The ratio of the labeling substance and the lectin to be subjected to these reactions can be appropriately selected so as to achieve the above-mentioned preferred content ratio.

[0079] When the labeled lectin is allowed to coexist in the measurement step, the labeled lectin may be added in advance to the sample or sample dilution solution, or may be added in advance to a solution of the blocked labeled lectin, or these may be mixed with the solution of the labeled lectin. In this case, the amount of the labeled lectin is not particularly limited, but in a reaction solution containing the sample, the blocked labeled lectin, and the labeled lectin, the content of the labeled lectin (when the labeled lectin is a combination of two or more types, the total amount of the labeled lectins) relative to 100 parts by mass of the blocked labeled lectin is preferably 1 to 1,000 parts by mass, more preferably 10 to 500 parts by mass.

[0080] In the measurement step of the lectin-binding substance measurement method of the present invention, it is also preferable to cause both the labeled lectin and the second water-soluble polymer to coexist, that is, to react the blocked labeled lectin with the lectin-binding substance and to react the labeled lectin with the lectin-binding substance under conditions in which the blocked labeled lectin, the labeled lectin, the second water-soluble polymer, and the sample (lectin-binding substance) coexist.

[0081] [Free lectin] In the lectin-binding substance measurement method of the present invention, the measurement step, i.e., the reaction between the blocked labeled lectin and the lectin-binding substance, is preferably carried out in the presence of free lectin, i.e., under conditions in which the free lectin, the blocked labeled lectin, and the sample (lectin-binding substance) coexist. In addition, in the lectin-binding substance measurement method, the measurement step is preferably carried out under conditions in which a second water-soluble polymer further coexists, i.e., under conditions in which the blocked labeled lectin, the second water-soluble polymer, the free lectin, and the sample coexist. Furthermore, it is also preferable to carry out the measurement under conditions in which the labeled lectin coexists, i.e., under conditions in which the blocked labeled lectin, the labeled lectin, the free lectin, and the sample coexist. Furthermore, it is also preferable to carry out the measurement under conditions in which the second water-soluble polymer and the labeled lectin all coexist, i.e., under conditions in which the blocked labeled lectin, the second water-soluble polymer, the labeled lectin, the free lectin, and the sample coexist.

[0082] The free lectin that is preferably allowed to coexist with the blocked labeled lectin is a free lectin (hereinafter referred to as "free lectin") that is not fixed to the water-soluble carrier or the labeled substance, unlike the lectin contained in the blocked labeled lectin and the lectin contained in the labeled lectin. In a method for measuring a lectin-binding substance using a lectin, the lectin nonspecifically binds to substances other than the target substance (for example, lectin-recognizing sugar chains bound to non-target proteins, etc.), so that the background tends to be high. However, in the method for measuring a lectin-binding substance of the present invention, the coexistence of the free lectin in the measurement step makes it possible to further suppress the increase in the background. The present inventors speculate that one of the reasons for this is the moderate masking effect of the free lectin. In addition, the coexistence of the free lectin may improve the reactivity of the blocked labeled lectin. The inventors speculate that the reason for this is that when the polyvalent free lectin binds monovalently to the sugar chain structure of the blocked labeled lectin, the apparent valency of the blocked enzyme-labeled lectin is increased, or that the addition of the free lectin increases the local lectin concentration, thereby causing the parallel reaction of binding and dissociation between the blocked labeled lectin and the lectin-binding substance to lean toward binding.

[0083] Examples of such free lectins include those listed above as lectins, and one of these may be used alone or in combination of two or more. The lectin may be the same type as the lectin contained in the blocked labeled lectin. Among these, from the viewpoint of improving reactivity and suppressing background, the free lectin is preferably at least one selected from the group consisting of Lens lectin (LCA), Cannabis sativa lectin I (MAM), Acanthus nigricans lectin (AAL), and Wisteria sieboldii lectin (WFA), more preferably at least one selected from the group consisting of Lens lectin (LCA) and Acanthus nigricans lectin (AAL), even more preferably any one of these, and particularly preferably the same type as the lectin contained in the blocked labeled lectin.

[0084] When the free lectin is allowed to coexist in the measurement step, the free lectin may be added in advance to the sample or sample dilution solution, may be added in advance to a solution of the blocked labeled lectin, or may be mixed with the solution of the free lectin. In this case, the amount of the free lectin is not particularly limited, but in a reaction solution containing the sample, the blocked labeled lectin (or the blocked labeled lectin and the labeled lectin), and the free lectin, the content of the free lectin (when the free lectin is a combination of two or more kinds, the total content of the blocked labeled lectin and the labeled lectin) per 100 parts by mass of the content of the blocked labeled lectin (or the total content of the blocked labeled lectin and the labeled lectin) is preferably 1 to 10,000 parts by mass, more preferably 10 to 5,000 parts by mass.

[0085] In the method for measuring a lectin-binding substance of the present invention, the sample may be one diluted with a sample dilution solution or one prepared after the purification treatment, and when the water-insoluble carrier in the sandwich method is a particle, the sample may be one suspended in a particle suspension medium. Furthermore, in the method for measuring a lectin-binding substance of the present invention, other reaction buffers may be appropriately added to the reaction system between the capture body and the detection body and the sample in the sandwich method. These sample dilution solutions, particle suspension mediums, and reaction buffers include the same ones as those listed in the above purification treatment, and are not particularly limited and can each be appropriately selected.

[0086] <Lectin-binding substance measurement kit> The lectin-binding substance measuring kit of the present invention comprises at least the blocked labeled lectin of the present invention as a constituent reagent. It is preferable that the kit further comprises at least one selected from the group consisting of a second water-soluble polymer, the labeled lectin, the free lectin, and the capture carrier. Each of these may be in a solid (powder) form or in a liquid form dissolved in a buffer solution. When in a liquid form, the concentrations of the blocked labeled lectin, the labeled lectin, and the capture carrier in each solution (preparation) are not particularly limited, but from the viewpoint that excessive addition of the blocked labeled lectin, the labeled lectin, and the capture carrier may tend to increase non-specific signals in some cases, each of them is preferably 0.01 to 10 μg / mL, more preferably 0.1 to 5.0 μg / mL, and even more preferably 0.5 to 3.0 μg / mL. The concentration of the second water-soluble polymer is preferably 0.01 to 10.0 w / v%, more preferably 0.1 to 5.0 w / v%, and even more preferably 0.5 to 3.0 w / v%. Furthermore, the concentration of the free lectin is preferably 1 μg / mL or more, more preferably 10 to 500 μg / mL, and even more preferably 50 to 250 μg / mL.

[0087] The lectin-binding substance measurement kit of the present invention may further include components to be included in normal immunological measurements such as ELISA, CLEIA, immunochromatography, etc. For example, when the above-mentioned sandwich method is used as the principle of the measurement method, the kit may further include at least one selected from the group consisting of a magnetic particle liquid containing magnetic beads on which a capture body is (or will be) immobilized or a plate on which the capture body is (or will be) immobilized, a standard specimen reagent (each concentration), a control reagent, the sample dilution solution, the particle suspension medium, the reaction buffer, the washing solution, and a dilution cartridge.

[0088] Furthermore, when the labeled substance is an enzyme, the kit may further comprise a substrate, a reaction stop solution, and the like, which are necessary for detecting and quantifying the labeled substance. Furthermore, the lectin-binding substance measurement kit of the present invention may further comprise a pretreatment solution for pretreatment of the sample, if necessary. Furthermore, when immunochromatography is employed as the sandwich method, the kit may further comprise a device including a zone carrying the blocked labeled lectin. The device may comprise other components suitable for immunochromatography, such as a developing solution pad or an absorbent pad. Furthermore, the lectin-binding substance measurement kit of the present invention may further comprise an instruction manual for using the kit. EXAMPLES

[0089] The present invention will be described in more detail below with reference to examples and comparative examples, but the present invention is not limited to the following examples. In each example and comparative example, "%" indicates weight / volume (w / v: g / mL) percentage unless otherwise specified.

[0090] Example 1 Measurement of alpha-fetoprotein L3 fraction (AFP-L3) using blocked labeled lectin and labeled lectin (1) Preparation of hydrazide dextran 240.0 mg of dextran (CarboMer) with a molecular weight of 250K was added to 4.8 mL of 0.1 M phosphate buffer (pH 7.0) and stirred for 30 minutes in the dark at 25 °C to dissolve. Then, 2.664 mL of 150 mM NaIO4 and 0.536 mL of ion-exchanged water were added and stirred for 30 minutes in the dark at 25 °C. Buffer exchange was performed with 0.1 M sodium phosphate buffer (pH 6.0) using a PD-10 column (GE Healthcare, Sephadex G-25 packed column) to obtain 20.0 mL of solution. 5.04 g of NH2NH2·HCl was added and stirred for 2 hours in the dark at 25 °C. 800 mg of DMAB (dimethylamine borane) was added and stirred for another 2 hours in the dark at 25 °C. The mixture was dialyzed against 4 L of ion-exchanged water using a RC50K (regenerated cellulose with a molecular weight of 50,000) dialysis membrane in the dark for 3 hours, and then allowed to stand overnight at 4°C. Buffer exchange was performed by gel filtration (Sephadex G-25) using 0.1 M sodium phosphate buffer (pH 6.0) to obtain 85.0 mL of solution. The concentration of dextran was adjusted to 1.0 mg / mL to obtain a solution of hydrazide dextran.

[0091] (2) Preparation of dextran-enzyme conjugates 30.0 mL of 10 mg / mL alkaline phosphatase (Oriental Yeast Co., Ltd., ALP-50) was subjected to buffer exchange by gel filtration (Sephadex G-25) using 0.1 M sodium phosphate buffer (pH 6.0) to prepare 90.6 mL of 3.0 mg / mL solution. 45.3 mL of 27 mM NaIO4 was added and stirred for 3 minutes in the dark at 25 ° C. Buffer exchange was performed by gel filtration (Sephadex G-25) using 0.1 M sodium phosphate buffer (pH 6.0) to prepare 0.5 mg / mL solution. 1.0 mg / mL hydrazide dextran prepared in (1) of Example 1 was added so that the concentration of hydrazide group (amino group) was 25 μM, and the mixture was stirred for 16 hours in the dark at 25 ° C. 85 mg of DMAB was added and the mixture was stirred for 2 hours in the dark at 25 ° C. Next, 10.1 mL of 1.5 M Tris buffer (pH 9.0) was added, and the mixture was stirred for 2 hours in the dark at 25° C. An ultrafiltration module (Pellicon XL50, Merck Millipore) was attached to a Labscale TFF System (Merck Millipore), and the mixture was concentrated to 15 mL, and gel filtration (Superdex 200 pg) was performed using 0.1 M sodium phosphate buffer (pH 7.0) to obtain 14 mL of a 3.0 mg / mL solution of the dextran-enzyme conjugate.

[0092] (3) Maleimide-PEGylation of dextran-enzyme conjugates 0.1M sodium phosphate buffer (pH 7.0) was added to the dextran-enzyme conjugate prepared in Example 1(2) to prepare 750μL of 2mg / mL dextran-enzyme conjugate. 8.35μL of 250mM SM(PEG)4 (Thermo Fisher Scientific, SM(PEG)4) dissolved in DMSO was added and mixed, and the mixture was mixed by inversion in a dark place at 25℃ for 1 hour. After the reaction, the buffer was exchanged with 0.1M sodium phosphate buffer (pH 6.3) containing 20mM EDTA·2Na and 0.5% CHAPS using a PD-10 column (Sephadex G-25). After the buffer exchange, the maleimide-PEGylated dextran-enzyme conjugate was concentrated using a centrifugal filter (Merck, Amicon Ultra 50K) to adjust the final concentration to 2mg / mL.

[0093] (4) Thiolation of lectins 5 mg of lentil lectin (LCA; J-Chemical) was dissolved in 2.5 mL of 0.1 M sodium phosphate buffer (pH 7.0) to obtain a 2 mg / mL LCA solution. 100 μL of 0.5 M EDTA·2Na (pH 8.0) was added to the 2.5 mL LCA solution, mixed, and then 75 μL of 10 mg / mL 2-iminothiolane hydrochloride solution was added and mixed by inversion in a dark place at 25 °C for 1 hour. After the reaction, the buffer was exchanged using a PD-10 column (Sephadex G-25) with 0.1 M sodium phosphate buffer (pH 6.3) containing 20 mM EDTA·2Na and 0.5% CHAPS. After the buffer exchange, the LCA concentration was adjusted to 650 μg / mL.

[0094] (5) Coupling 10 μL of 1M Glucose was added to 2 mL of LCA prepared to 650 μg / mL by thiolation obtained in (4) of Example 1, and the mixture was mixed by inversion for 30 minutes in a dark place at 25°C. Next, 500 μL of the maleimide-PEGylated dextran-enzyme conjugate solution (2 mg / mL) obtained in (3) of Example 1 was added, and the mixture was mixed by inversion for 1 hour in a dark place at 25°C, thereby coupling the LCA with the dextran-enzyme conjugate. After the reaction, 25 μL of 200 mM 3-Mercapto-1,2-propanediol was added, and the mixture was mixed by inversion for 30 minutes in a dark place at 25°C. After that, 50 μL of 200 mM 2-Iodoacetamide was added, and the mixture was mixed by inversion for 30 minutes in a dark place at 25°C. The reaction solution was concentrated using a centrifugal filter (Merck, Amicon Ultra 50K) and then passed through a φ0.22 μm filter and purified by gel filtration chromatography (column: Superose 6 Increase 10 / 300 GL, buffer: 0.1 M MES, 0.5 M NaCl, 1 mM MgCl2, 0.1 mM ZnCl2, 5 mM Glucose, 0.05% CHAPS, pH 6.8), finally obtaining 2 mL of a solution of 167.4 μg / mL blocked labeled lectin 1 (dextran-enzyme-LCA conjugate).

[0095] (6) Preparation of labeled lectin 5 mg of lentil lectin (LCA; J-Chemical) was dissolved in 1 mL of 0.1 M sodium phosphate buffer (pH 7.0) to obtain a 5 mg / mL LCA solution. 41 μL of 10 mg / mL Sulfo-EMCS (Dojindo Laboratories) was added to 1 mL of the LCA solution, and the mixture was mixed by inversion in a dark place at 25 °C for 1 hour. After the reaction, the buffer was exchanged with 0.1 M sodium phosphate buffer (pH 6.0) containing 0.5% CHAPS using a NAP-10 column (GE Healthcare, Sephadex G-25 packed column), and the recovered maleimide-modified LCA was adjusted to a concentration of 2.5 mg / mL.

[0096] 300μL of 10mg / mL alkaline phosphatase (Oriental Yeast, ALP-50) was buffer exchanged with 0.1M sodium phosphate buffer (pH 7.0) using a NAP-5 column (GE Healthcare, Sephadex G-25 packed column) to obtain 0.8mL of 3.4mg / mL ALP solution. Next, 13.2μL of 10mg / mL 2-iminothiolane hydrochloride solution was added and mixed by inversion in a dark place at 25℃ for 1 hour. After the reaction, buffer exchange was performed using a NAP-10 column (Sephadex G-25) with 0.1M sodium phosphate buffer (pH 6.0) containing 0.5% CHAPS, and the recovered thiolated ALP was adjusted to a concentration of 1.8mg / mL.

[0097] 1.07 mL of 2.5 mg / mL maleimide-modified LCA and 0.83 mL of 1.8 mg / mL thiolated ALP were mixed and left to stand for 20 hours in a dark place at 25 ° C. to couple LCA and ALP. After the reaction, 19 μL of 150 mM 3-Mercapto-1,2-propanediol was added and left to stand for 1 hour in a dark place at 25 ° C. The reaction solution was concentrated using a centrifugal filter (Merck, Amicon Ultra 50K) and then passed through a φ0.22 μm filter and purified by gel filtration chromatography (column: Superdex200 PG, buffer: 0.1 M MES, 0.15 M NaCl, 1 mM MgCl2, 1 mM ZnCl2, 0.3 M methyl-α-D-mannopyranoside, 0.05% CHAPS, 0.9% NaN3, pH 6.8), finally obtaining 1 mL of a solution of 543 μg / mL labeled lectin 1 (ALP-LCA conjugate).

[0098] (7) Measurement of AFP-L3 Magnetic particles (manufactured by Fujirebio Inc.) were reacted with anti-AFP monoclonal antibody F(ab')2 fragments (manufactured by Fujirebio Inc.) to immobilize the antibody fragments on the particles. The particles with the immobilized antibody fragments were diluted with a particle diluent (50 mM Tris, 100 mM KCl, 0.5% BSA, pH 7.2) to a particle concentration of 0.01%, to prepare an anti-AFP antibody F(ab')2 fragment-bound particle solution.

[0099] As samples, cancer mutant AFP antigen (serum-free supernatant of Huh7 cell culture, AFP-L3 content 93.3%, hereinafter also referred to as "L3 antigen") was diluted with Carbo-Free Blocking Solution (CFB; VECTOR) to 1.6, 3.1, 6.3, 12.5, 25, 50, 100, or 200 ng / mL to prepare each L3 antigen sample solution. In addition, as a reference sample, healthy human AFP antigen (LEE Biosolutions, AFP-L3 content 7.8%, hereinafter also referred to as "L1 antigen") was also diluted with CFB to 200 ng / mL to prepare an L1 antigen sample solution.

[0100] The blocked labeled lectin 1 obtained in Example 1(5) and the labeled lectin 1 obtained in Example 1(6) were diluted with a labeled body diluent (30 mM MES, 360 mM NaCl, 1.5% arginine, 0.06% hydrazine hydrochloride, 0.06 mM ZnCl2, 0.6 mM MgCl2, 30 μg / mL inactivated ALP, 30 μg / mL Mouse KLG, 2.4% C14APS, 0.15% Tween 20, 1×CFB, 1% Tergitol 15-s-7, 0.0005% Antiform SI) to 0.5 μg / mL, respectively, to prepare each labeled body solution of blocked labeled lectin 1 and labeled lectin 1. Free dextran 2000K (Sigma) was added to each labeled body solution to a concentration of 0, 1.0, 2.0, or 3.0%.

[0101] The L1 antigen sample solution and the L3 antigen sample solution were subjected to AFP-L3 measurement using Lumipulse (registered trademark) L-2400 (manufactured by Fujirebio Inc.). 50 μL of each sample solution was mixed with 50 μL of the anti-AFP antibody F(ab')2 fragment-bound particle solution and reacted at 37°C for 8 minutes. Next, the magnetic particles were collected and washed five times with Lumipulse (registered trademark) washing solution (manufactured by Fujirebio Inc.). Next, 50 μL of each of the above labeled body solutions was added and reacted at 37°C for 8 minutes. Next, the magnetic particles were collected and washed five times, after which 50 μL of Lumipulse (registered trademark) substrate solution (manufactured by Fujirebio Inc.) containing AMPPD (3-(2'-spiroadamantane)-4-methoxy-4-(3'-phosphoryloxy)phenyl-1,2-dioxetane disodium salt) was added and reacted at 37°C for 4 minutes. The amount of light emitted with maximum absorption at a wavelength of 463 nm, which is emitted when AMPPD is decomposed by the catalytic action of alkaline phosphatase of blocked labeled lectin 1 or labeled lectin 1 bound to magnetic particles, was measured. The measurement results were output as the luminescence intensity (counts) of the substrate. The measurement results under each condition are shown in Table 1 below. The results shown are the average values ​​of duplicate measurements minus the blank value obtained by measuring only the buffer.

[0102] [Table 1]

[0103] As shown in Table 1, it was confirmed that both blocked labeled lectin 1 and labeled lectin 1 hardly bind to L1 antigens, but bind to L3 antigens. In particular, when blocked labeled lectin 1 of the present invention was used (Examples 1-1 to 1-4), a higher signal was obtained than when labeled lectin 1 was used (Comparative Examples 1-1 to 1-4), suggesting that measurement with higher sensitivity is possible. Furthermore, it was confirmed that when free dextran was added to each labeled body fluid, the signal when blocked labeled lectin 1 was used was significantly higher than that when labeled lectin 1 was used.

[0104] Example 2 Measurement of PSA derived from prostate cancer cells using blocked labeled lectin and labeled lectin 1 (1) Preparation of blocked labeled lectin using AAL A 2.0 mL solution of 87.8 μg / mL blocked labeled lectin 2 (dextran-enzyme-AAL conjugate) was obtained in the same manner as in (1) to (5) of Example 1, except that Acanthopanax lectin (AAL; manufactured by VECTOR) was used instead of lentil lectin (LCA).

[0105] (2) Preparation of labeled lectins using AAL A 2.0 mL solution of 34.4 μg / mL labeled lectin 2 (ALP-AAL conjugate) was obtained in the same manner as in (6) of Example 1, except that Acanthopanax lectin (AAL; manufactured by VECTOR) was used instead of lentil lectin (LCA).

[0106] (3) Measurement of PSA derived from cancer cells Magnetic particles (manufactured by Fujirebio Inc.) were reacted with anti-PSA monoclonal antibody F(ab')2 fragments (manufactured by Fujirebio Inc.) to immobilize the antibody fragments on the particles. The particles with the immobilized antibody fragments were diluted with a particle diluent (50 mM Tris, 100 mM KCl, 0.5% BSA, pH 7.2) to a particle concentration of 0.01%, to prepare an anti-PSA antibody F(ab')2 fragment-bound particle solution.

[0107] Either the blocked labeled lectin 2 (dextran-enzyme-AAL conjugate) obtained in Example 2(1) or the labeled lectin 2 (ALP-AAL conjugate) obtained in Example 2(2) was added to PBS (pH 7.4) containing 1.0% BSA, 2.0% free dextran 2000K, and 0.0005% Antiform SI so as to give a concentration of 0.5 μg / mL, to prepare each labeled body fluid of blocked labeled lectin 2 or labeled lectin 2. In addition, as a sample, PSA (LNCap-PSA) derived from cultured prostate cancer cells (LNCaP) was diluted with CFB to prepare a specimen solution with a concentration of LNCap-PSA of 50 ng / mL.

[0108] Cancer cell-derived PSA was measured in the same manner as in Example 1(7), except that each of the labeled body fluids, specimen solutions, and anti-PSA antibody F(ab')2 fragment-bound particle solutions were used. The measurement results of cancer cell-derived PSA under each condition (luminescence intensity (counts) of the substrate) are shown in Table 2 below. The results shown are the average values ​​of duplicate measurements minus the blank value obtained by measuring only the buffer.

[0109] [Table 2]

[0110] Table 2 shows that cancer cell-derived PSA can be detected by both blocked labeled lectin 2 and labeled lectin 2. In particular, when blocked labeled lectin 2 was used (Example 2-1), a higher signal was obtained than when labeled lectin 2 was used (Comparative Example 2-1), suggesting that measurement with higher sensitivity is possible.

[0111] Example 3 Measurement of AFP-L3 using a mixture of blocked labeled lectins (1) Preparation of blocked labeled lectin Each blocked labeled lectin was prepared in the same manner as in (1) to (5) of Example 1, except that dextran having a molecular weight of 500K (Fluka) or dextran having a molecular weight of 70K (TCI) was used as the dextran. The blocked labeled lectin using dextran having a molecular weight of 500K is referred to as "blocked labeled lectin 3 (500K)," and the blocked labeled lectin using dextran having a molecular weight of 70K is referred to as "blocked labeled lectin 4 (70K)."

[0112] (2) AFP-L3 measurement 1 An anti-AFP antibody F(ab')2 fragment-bound particle solution was prepared in the same manner as in (7) of Example 1, except that the particle dilution solution was 50 mM Tris, 150 mM NaCl, 2 mM EDTA 2Na, 0.5 mg / mL sodium dextran sulfate 5,000, 30 μg / mL mouse KLG, 1.0% BSA, 0.005% Antiform SI, 0.1% ProClin 300, pH 7.2.

[0113] Furthermore, each sample solution was prepared in the same manner as in (7) of Example 1, except that the L3 antigen was diluted to a concentration of 1.0, 2.0, 3.9, 7.8, 15.6, 31.3, 62.5, 125, or 250 ng / mL.

[0114] Blocked labeled lectin 3 (500K), blocked labeled lectin 4 (70K), or labeled lectin 1 obtained in Example 1(6) was diluted with a label diluent (30 mM MES, 360 mM NaCl, 1.5% arginine, 0.06% hydrazine hydrochloride, 0.06 mM ZnCl2, 0.6 mM MgCl2, 30 μg / mL inactivated ALP, 30 μg / mL mouse KLG, 2.4% C14APS, 0.15% Tween 20, 1×CFB, 1% Tergitol 15-s-7, 1.0% free dextran 2000K, 50 μg / mL free LCA, 0.0005% Antiformaldehyde, 0.02% EDTA, 0.01 ... The samples were diluted with 500K SI) to a concentration of 0.5 μg / mL to prepare three types of labeled solutions: blocked labeled lectin 3 (500K) solution, blocked labeled lectin 4 (70K) solution, and labeled lectin 1 solution.

[0115] AFP-L3 was measured in the same manner as in Example 1(7), except that each of the labeled body fluids, each of the specimen solutions, and the anti-AFP antibody F(ab')2 fragment-bound particle solution were used. The results of AFP-L3 measurement (substrate luminescence intensity (counts)) under each condition are shown in Table 3 below. The results shown are the average values ​​of duplicate measurements minus the blank value obtained by measuring only the buffer.

[0116] [Table 3]

[0117] As shown in Table 3, both blocked labeled lectin 3 (500K) (Example 3-1) and blocked labeled lectin 4 (70K) (Example 3-2) detected L3 antigen with extremely high sensitivity compared to labeled lectin 1 (Comparative Example 3-1), and in particular, blocked labeled lectin 3 (500K) detected L3 antigen with even higher sensitivity than blocked labeled lectin 4 (70K). These results show that the use of the blocked labeled lectin of the present invention allows the measurement of the analyte (AFP-L3) with higher sensitivity than the labeled lectin, and further shows that the use of dextran with a larger molecular size during the preparation of the blocked labeled lectin allows the measurement of the analyte with even higher sensitivity, even at low concentrations.

[0118] (3) AFP-L3 measurement 2 Each sample solution was prepared in the same manner as in (7) of Example 1, except that the L3 antigen was diluted to the respective concentrations (2.0 to 2000 ng / mL) shown in Table 4 below. In addition, the blocked labeled lectin 3 (500K), blocked labeled lectin 4 (70K), and labeled lectin 1 obtained in Example 1(6) were each diluted to 0.5 μg / mL in labeled body diluent (30 mM MES, 360 mM NaCl, 1.5% arginine, 0.06 mM ZnCl2, 0.6 mM MgCl2, 2.4% C14APS, 0.15% Tween 20, 1×CFB, 1% Tergitol 15-s-7, 1% free dextran 2000K, 50 μg / mL free LCA, 0.0005% Antiform SI) at the concentrations and combinations shown in Table 4 below to prepare three types of labeled body solutions, i.e., blocked labeled lectin 3 (500K) solution, blocked labeled lectin 4 (70K) solution, and labeled lectin 1 solution.

[0119] AFP-L3 was measured in the same manner as in Example 1(7), except that each of the above sample solutions and each of the labeled body fluids were used. The measurement results of AFP-L3 under each condition (luminescence intensity (counts) of the substrate) are shown in Table 4 and Figure 1 below. The results shown are the average values ​​of duplicate measurements minus the blank value obtained by measuring only the buffer.

[0120] [Table 4]

[0121] As shown in Table 4 and Figure 1, it was confirmed that by combining multiple blocked labeled lectins with different dextran molecular weights and further combining labeled lectins, it became possible to more accurately quantify even samples containing high concentrations of the analyte (AFP-L3).

[0122] Example 4 Sample purification for serum AFP-L3 measurement The samples prepared were a CFB containing 200 ng / mL of L3 antigen (B1, buffer sample), healthy human serum with 200 ng / mL of L3 antigen added (S1, serum sample), and healthy human serum without added L3 antigen (S2, serum sample).

[0123] (1) Sample purification 40 μL of anti-AFP antibody-bound particles (manufactured by Fujirebio Inc.) was mixed with 300 μL of each serum sample (S1 or S2), and the mixture was stirred and shaken at room temperature for 40 seconds. After the magnetic particles were collected and the supernatant was removed, the mixture was washed three times with 300 μL of Lumipulse (registered trademark) washing solution. 200 μL of elution solution (0.1 M Glycine, 0.3 M NaCl, 0.2% TritonX-100, 1×CFB, pH 2.1) was added, and the mixture was stirred and shaken at room temperature for 20 seconds. The supernatant was transferred to another container, neutralized by adding 10 μL of 2 M Tris (pH 10.0), and then 90 μL of CFB was added to prepare a purified sample.

[0124] (2) Measurement of AFP-L3 The blocked labeled lectin 1 obtained in Example 1(5) or the labeled lectin 1 obtained in Example 1(6) was diluted with labeled body diluent (30 mM MES, 360 mM NaCl, 1.5% arginine, 0.06 mM ZnCl2, 0.6 mM MgCl2, 30 μg / mL inactivated ALP, 30 μg / mL mouse KLG, 2.4% C14APS, 0.15% Tween 20, 1×CFB, 1% Tergitol 15-s-7, 2% free dextran 2000K, 0.0005% Antiform SI) to a concentration of 0.5 μg / mL to prepare labeled body solutions of blocked labeled lectin 1 and labeled lectin 1, respectively.

[0125] For S1 and S2 that had been subjected to the purification treatment of Example 4(1), AFP-L3 was measured in the same manner as in Example 1(7), except that each of the labeled body fluids described above was used. In addition, AFP-L3 was measured for S1, S2, and B1 under conditions other than the above, without the purification treatment of Example 4(1). The measurement results of AFP-L3 under each condition (luminescence intensity (counts) of the substrate) are shown in Table 5 below. The results shown are the average values ​​of duplicate measurements minus the blank value obtained by measuring only the buffer.

[0126] [Table 5]

[0127] As shown in Table 5, under the condition that no purification treatment was performed, a high signal was detected in the healthy human serum sample (S2). However, when the blocked labeled lectin 1 of the present invention was used (Example 4-1), a higher signal was obtained from the serum sample (S1) containing more AFP-L3 than when the labeled lectin 1 was used (Comparative Example 4-1), and it was confirmed that the detection of the analyte (AFP-L3) itself was sufficiently possible. Furthermore, as a result of the purification treatment, the signal of the serum sample (S1) containing more AFP-L3 was also reduced, but the signal of the healthy human serum sample (S2) was significantly reduced, suggesting that the non-measured substance can be measured with higher accuracy.

[0128] Example 5 Lectin species evaluation of blocked labeled lectins and their specificity for prostate cancer cell-derived PSA 1 (1) Preparation of blocked labeled lectin using MAM A 3.5 mL solution of 182.7 μg / mL blocked labeled lectin 5 (MAM) (dextran-enzyme-MAM conjugate) was obtained in the same manner as in (1) to (5) of Example 1, except that canine solanaceous lectin (canine solanaceous lectin I: MAM; manufactured by J-Chemical Co., Ltd.) was used instead of lentil lectin (LCA).

[0129] (2) Measurement of PSA derived from cancer cells Into each well of a 96-well microwell plate (Nunc MAXISORP, black, 16-well module × 4), 50 μL / well of PBS (pH 7.4) containing 0.1 μg / mL of cultured prostate cancer cell (LNCaP)-derived PSA (LNCap-PSA) or 0.1 μg / mL of human seminal plasma (HSF)-derived PSA (HSF-PSA) or PBS (pH 7.4) containing only 1.0% BSA without any PSA was dispensed as a sample. After incubation at 37 ° C for 1.5 hours, the plate was washed three times with PBST (0.1% Tween20 in PBS, pH 7.4) and once with PBS (pH 7.4). Next, 150 μL / well of blocking solution (1.0% BSA / PBS, pH 7.4) was dispensed, and the plate was left to stand at 37 ° C for 2 hours and then stored at 4 ° C.

[0130] After removing the blocking solution, 50 μL / well of PBS (pH 7.4) containing 0.5 μg / mL blocked labeled lectin 5 (MAM), 1.0% BSA, and 0-3.0% free dextran 2000K was dispensed, and after 1.5 hours of incubation at 37°C, the plate was washed three times with PBST and then once with PBS (pH 7.4). Next, 50 μL / well of Lumipulse (registered trademark) substrate solution, which had been pre-warmed to 37°C, was dispensed, and after 5 minutes, the amount of light emitted with a maximum absorption at a wavelength of 463 nm was measured using a microplate reader. The measurement results were output as the luminescence intensity (counts) of the substrate. The measurement results under each condition are shown in Table 6 below. The results shown are the average values ​​of duplicate measurements.

[0131] [Table 6]

[0132] As shown in Table 6, a strong signal was detected only on the plate on which LNCap-PSA was immobilized. It was also confirmed that the signal was further enhanced under conditions containing free dextran. On the other hand, there was almost no difference in the signal between the plate on which HSF-PSA was immobilized and the plate on which BSA was immobilized, suggesting that blocked labeled lectin 5 (MAM) hardly reacts with HSF-PSA. From these results, it was confirmed that the blocked labeled lectin of the present invention specifically binds to cancer-derived PSA even when canine solanaceous lectin (MAM) is used as the lectin.

[0133] Example 6 Lectin species evaluation of blocked labeled lectins and specificity evaluation for prostate cancer cell-derived PSA 2 (1) Preparation of blocked labeled lectin using WFA A 2.0 mL solution of 373.9 μg / mL blocked labeled lectin 6 (WFA) (dextran-enzyme-WFA conjugate) was obtained in the same manner as in (1) to (5) of Example 1, except that Wisteria nodalis lectin (WFA; manufactured by VECTOR) was used instead of lentil lectin (LCA).

[0134] (2) Measurement of PSA derived from cancer cells Magnetic particles (manufactured by Fujirebio Inc.) were reacted with anti-PSA monoclonal antibody F(ab')2 fragments (manufactured by Fujirebio Inc.) to immobilize the antibody fragments on the particles. The particles with the immobilized antibody fragments were diluted with a particle diluent (50 mM Tris, 100 mM KCl, 0.5% BSA, pH 7.2) to a particle concentration of 0.01%, to prepare an anti-PSA antibody F(ab')2 fragment-bound particle solution.

[0135] Blocked labeled lectin 5 (MAM) (dextran-enzyme-MAM conjugate) obtained in Example 5(1), blocked labeled lectin 2 (AAL) (dextran-enzyme-AAL conjugate) obtained in Example 2(1), and blocked labeled lectin 6 (WFA) (dextran-enzyme-WFA conjugate) obtained in Example 6(1) were added at 0.5 μg / mL, and 0, 1.0, or 2.0% free dextran 2000K was added to PBS (pH 7.4) containing 1.0% BSA to prepare labeled body fluids of blocked labeled lectins 2, 5, and 6, respectively. In addition, LNCap-PSA (PSA derived from cultured prostate cancer cells) was diluted with CFB to 1.6, 3.1, 6.3, 12.5, 25, or 50 ng / mL as a sample, and each specimen solution was prepared.

[0136] Cancer cell-derived PSA was measured in the same manner as in Example 1 (7), except that each of the labeled body fluids, each of the specimen solutions, and the anti-PSA antibody F(ab')2 fragment-bound particle solution were used. The measurement results of cancer cell-derived PSA under each condition (luminescence intensity (counts) of the substrate) are shown in Table 7 below. The results shown are the average values ​​of duplicate measurements minus the blank value obtained by measuring only the buffer.

[0137] [Table 7]

[0138] As shown in Table 7, it was confirmed that the blocked labeled lectin of the present invention can specifically bind to cancer cell-derived PSA regardless of whether the lectin used was Mucor elegans lectin (MAM), Atractylodes gracilis lectin (AAL), or Wisteria sieboldii lectin (WFA). It was also confirmed that the signal detecting cancer cell-derived PSA was significantly enhanced by adding free dextran to the labeled body fluid.

[0139] Example 7 Measurement of PSA derived from prostate cancer cells using blocked labeled lectin and labeled lectin 2 (1) Preparation of blocked labeled lectin using MAM A solution of blocked labeled lectin 7 (dextran 500K-enzyme-MAM conjugate: "blocked labeled lectin 7 (500K)") was obtained in the same manner as (1) to (5) of Example 1, except that canine solanaceous lectin (canine solanaceous lectin I: MAM; manufactured by J-Chemical Co., Ltd.) was used instead of lentil lectin (LCA) and dextran with a molecular weight of 500K (manufactured by Fluka) was used as dextran.

[0140] (2) Preparation of labeled lectins using MAM A solution of labeled lectin 3 (ALP-MAM conjugate) was obtained in the same manner as in (6) of Example 1, except that canine solanaceous lectin (canine solanaceous lectin I:MAM; manufactured by J-Chemical Co., Ltd.) was used instead of lentil lectin (LCA).

[0141] (3) Measurement of PSA derived from cancer cells Either the blocked labeled lectin 5 (MAM) obtained in Example 5(1) (dextran 250K-enzyme-MAM conjugate: “blocked labeled lectin 5 (250K)”), the blocked labeled lectin 7 (500K) obtained in Example 7(1), or the labeled lectin 3 obtained in Example 7(2) was added to a dilution solution (PBS containing 1.0% BSA, 2.0% free dextran 2000K, and 0.0005% Antiform SI, pH 7.4) to a concentration of 0.5 μg / mL to prepare labeled body fluids of blocked labeled lectin 5 (250K), blocked labeled lectin 7 (500K), and labeled lectin 3, respectively. Furthermore, as samples, LNCap-PSA (PSA derived from cultured prostate cancer cells) was diluted with CFB to 1.56, 3.13, 6.25, 12.5, 25, or 50 ng / mL to prepare sample solutions.

[0142] Cancer cell-derived PSA was measured in the same manner as in Example 6(2), except that each of the labeled body fluids and each of the sample solutions described above were used. The measurement results (luminescence intensity (counts) of the substrate) under each condition are shown in Table 8 below. The results shown are the average values ​​of duplicate measurements minus the blank value obtained by measuring only the buffer.

[0143] [Table 8]

[0144] As shown in Table 8, both the blocked labeled lectin 5 (250K) (Example 7-1) and the blocked labeled lectin 7 (500K) (Example 7-2) detected LNCap-PSA with extremely high sensitivity compared to the labeled lectin 3 (Comparative Example 7-1), and in particular, the blocked labeled lectin 7 (500K) detected LNCap-PSA with even higher sensitivity than the blocked labeled lectin 5 (250K). These results show that even when canine lectin (MAM) is used as the lectin, the blocked labeled lectin of the present invention can measure the analyte (LNCap-PSA) with higher sensitivity than the labeled lectin, and further, when a dextran with a larger molecular size is used in the preparation of the blocked labeled lectin, the analyte can be measured with even higher sensitivity even at low concentrations.

[0145] Example 8 Measurement of PSA derived from prostate cancer cells using blocked labeled lectin (WFA) (1) Measurement of PSA derived from cancer cells As samples, LNCap-PSA (PSA derived from cultured prostate cancer cells) and HSF-PSA (PSA derived from human seminal plasma) were diluted with CFB to 0.39, 0.78, 1.56, 3.13, 6.25, 12.5, 25, or 50 ng / mL, respectively, to prepare sample solutions.

[0146] Except for using these sample solutions, the cancer cell-derived PSA was measured in the same manner as in Example 6(2) using blocked labeled lectin 6 (WFA). The measurement results (substrate luminescence intensity (counts)) under each condition are shown in Table 9 below. The results shown are the average values ​​of duplicate measurements minus the blank value obtained by measuring only the buffer.

[0147] [Table 9]

[0148] As shown in Table 9, a strong signal was detected when LNCap-PSA was measured. In comparison, the signal was very low when HSF-PSA was measured, suggesting that blocked labeled lectin 6 (WFA) hardly reacts with HSF-PSA. These results confirmed that the blocked labeled lectin of the present invention specifically binds to cancer cell-derived PSA even when Wisteria nodali lectin (WFA) is used as the lectin.

[0149] Example 9 Measurement of PSA derived from prostate cancer cells using a mixture of blocked labeled lectin (WFA) and labeled lectins (1) Preparation of labeled lectins using WFA A solution of labeled lectin 4 (ALP-WFA conjugate) was obtained in the same manner as in (6) of Example 1, except that Wisteria nodalis lectin (WFA; VECTOR) was used instead of lentil lectin (LCA).

[0150] (2) Measurement of PSA derived from cancer cells Either the blocked labeled lectin 6 (WFA) obtained in Example 6 (1) or the labeled lectin 4 obtained in Example 9 (1) was added to a dilution solution to a concentration of 0.5 μg / mL to prepare each of the labeled body fluids of the blocked labeled lectin 6 and the labeled lectin 4. Also, the blocked labeled lectin 6 (WFA) and the labeled lectin 4 were added to a dilution solution to a concentration of 0.5 μg / mL and 0.25 μg / mL, respectively, to prepare a labeled body fluid in which the blocked labeled lectin 6 and the labeled lectin 4 were mixed. Also, as a sample, LNCap-PSA (PSA derived from cultured prostate cancer cells) was diluted with healthy human serum to a concentration of 1, 5, 10, 25, or 50 ng / mL to prepare each sample solution.

[0151] Except for using each of the labeled body fluids and each of the sample solutions described above, the measurement of cancer cell-derived PSA was carried out in the same manner as in Example 6(2). The measurement results of cancer cell-derived PSA under each condition (luminescence intensity (counts) of the substrate) are shown in Table 10 below. The results shown are the average values ​​of duplicate measurements minus the blank values ​​obtained by measuring only healthy human serum.

[0152] [Table 10]

[0153] As shown in Table 10, blocked labeled lectin 6 (WFA) (Example 9-1) detected LNCap-PSA with extremely high sensitivity compared to labeled lectin 4 (Comparative Example 9-1). It was also confirmed that by combining blocked labeled lectin 6 (WFA) with labeled lectin 4 (Example 9-2), it became possible to more accurately quantify even samples containing a high concentration of the analyte (LNCap-PSA). [Industrial Applicability]

[0154] According to the present invention, it is possible to provide a lectin-binding substance measurement method and a lectin-binding substance measurement kit, which are capable of measuring a lectin-binding substance in a sample simply and with high sensitivity, as well as a blocked labeled lectin for use therein.

Claims

1. A method for measuring a lectin-binding substance in a sample, comprising: a measurement step of contacting the sample with a blocked labeled lectin comprising a water-soluble carrier made of a first water-soluble polymer and a labeled substance and a lectin immobilized on the water-soluble carrier, The measuring step is carried out in the presence of a second water-soluble polymer; The first water-soluble polymer and the second water-soluble polymer are dextran. Method for measuring lectin-binding substances.

2. the measuring step further includes a step of contacting the sample with a labeled lectin comprising a labeling substance and a lectin; the lectin of the blocked labeled lectin and the lectin of the labeled lectin are of the same kind; The method for measuring a lectin-binding substance according to claim 1 .

3. A method for measuring a lectin-binding substance in a sample, comprising: a measurement step of contacting the sample with a blocked labeled lectin comprising a water-soluble carrier made of a first water-soluble polymer and a labeled substance and a lectin immobilized on the water-soluble carrier, the measuring step further includes a step of contacting the sample with a labeled lectin comprising a labeling substance and a lectin; the first water-soluble polymer is dextran; the lectin of the blocked labeled lectin and the lectin of the labeled lectin are of the same kind; Method for measuring lectin-binding substances.

4. 4. The method for measuring a lectin-binding substance according to claim 3, wherein the measuring step is carried out in the presence of a second water-soluble polymer, and the second water-soluble polymer is dextran.

5. A composition for use in the method for measuring a lectin-binding substance according to any one of claims 1 to 4, comprising a water-soluble carrier made of a first water-soluble polymer, and a labeled substance and a lectin immobilized on the water-soluble carrier, the composition including a blocked labeled lectin in which the first water-soluble polymer is dextran.

6. A lectin-binding substance measurement kit for use in the lectin-binding substance measurement method described in any one of claims 1 to 4, comprising a water-soluble carrier consisting of a first water-soluble polymer, and a labeled substance and a lectin fixed to the water-soluble carrier, wherein the first water-soluble polymer contains a blocked labeled lectin which is dextran.

7. The kit for measuring a lectin-binding substance according to claim 6 , further comprising a second water-soluble polymer, the second water-soluble polymer being dextran.

8. 8. The kit for measuring a lectin-binding substance according to claim 6, further comprising a labeled lectin comprising a labeling substance and a lectin, wherein the lectin of the blocked labeled lectin and the lectin of the labeled lectin are of the same type.

Images